J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jafron Biomedical Co Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Retained Earnings
ÂĄ2.7B
CAGR 3-Years
15%
CAGR 5-Years
24%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Retained Earnings
ÂĄ1.1B
CAGR 3-Years
66%
CAGR 5-Years
54%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Retained Earnings
ÂĄ9.2B
CAGR 3-Years
17%
CAGR 5-Years
23%
CAGR 10-Years
24%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Retained Earnings
ÂĄ31B
CAGR 3-Years
26%
CAGR 5-Years
35%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Retained Earnings
ÂĄ11B
CAGR 3-Years
8%
CAGR 5-Years
14%
CAGR 10-Years
22%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Retained Earnings
ÂĄ4.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
47.02 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Retained Earnings?
Retained Earnings
2.7B CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Retained Earnings amounts to 2.7B CNY.

What is Jafron Biomedical Co Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
24%

Over the last year, the Retained Earnings growth was 18%. The average annual Retained Earnings growth rates for Jafron Biomedical Co Ltd have been 15% over the past three years , 24% over the past five years .

Back to Top